Top Picks 2020- Novartis NOVHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Top Picks 2020- Novartis NOVMoneyShowJanuary 9, 2020ReblogShareTweetShareJohn Eade, an analyst with Argus Research, chose defense contractor Lockheed Martin (LMT) as his Top Pick in 2019. He still views the stock — which rose 47% last year — as a suitable core holding in a diversified portfolio. For 2020, he turns to a favorite drug developer.Novartis (NOV) has historically generated stable earnings from its diverse businesses, which include its pharmaceutical and Sandoz generics groups, and has a deep new drug pipeline.See also::
Top Picks 2020: Macy's (M)The company completed a three-part deal in which it sold its vaccine business to GlaxoSmithKline (GSK), bought the Glaxo oncology business, and combined its consumer healthcare business in a joint venture with the Glaxo consumer healthcare business.Now, the joint venture has been sold back to Glaxo. The transaction is helping Novartis to focus on its strengths — autoimmune disorders, oncology and generics, including biosimilars — while exiting noncore businesses.Last April, the firm spun-off of its eye care division, Alcon (ALC). In conjunction with the spin-off, Novartis also announced its intention to continue paying a strong and growing annual dividend. In addition, management indicated that share buybacks will continue to be part of the mix to create shareholder value.See also: Top Picks 2020: Bank OZK (OZK)Over the next several years, we expect the Swiss company to launch new drugs in such critical areas as coronary disease, oncology and gene therapy.* Zolgensma gene therapy was launched in the U.S. for treatment of spinal muscular atrophy in children under the age of two* Piqray (alpelisib) launched for treatment of advanced breast cancer with a PIK3CA mutation* Beovu (brolucizumab) launched in the U.S. for treatment of neovascular (wet) AMD.* Ofatumumab (OMB157), a subcutaneous, potent, fully-human monoclonal antibody targeting CD20 positive B-cells, had positive Phase III trial results, and rolling submissions are planned to start in 4QThe company's 'growth products' include Cosentyx for psoriasis and other conditions, Jakavi for myelofibrosis, Entresto for chronic heart failure, and bone marrow stimulant Promacta/Revolade, Tafinlar + Mekinist for melanoma.Other recently launched products, Kisqali for advanced or metastatic breast cancer, Lutathera, for cancerous neuroendocrine tumors affecting the digestive tract, and Kymriah, a promising immune-oncology drug.Many of the drugs under development are considered breakthrough treatments and should benefit from strong pricing power. The company's balance sheet is clean and management has a history of increasing the dividend annually.More From MoneyShow.com:Top Picks 2020: ConocoPhillips (COP)Top Picks 2020: Turning Point Brands (TPB)Top Picks 2020: Starwood Property Trust, Inc. (STWD)Top Picks 2020: Avanex (AVXL)Top Picks 2020: Mastercard (MA)Top Picks 2020: Cisco Systems (CSCO)ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextHow Lockheed Martin Space is riding out the commercial satellite slumpAmerican City Business JournalsHouse Democrats to introduce bill clawing back border wall fundsReutersLockheed (LMT) Down 7.6% Since Last Earnings Report: Can It Rebound?ZacksDon't Race Out To Buy Novartis AG (VTX:NOVN) Just Because It's Going Ex-DividendSimply Wall St.The FTC wants to cut one of the coal industry’s last lifelinesQuartzBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoSalMar ASA Annual Results: Here's What Analysts Are Forecasting For Next YearSimply Wall St.'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance Video